|
Volumn 31, Issue 1-2, 1999, Pages 243-246
|
Immunologically high-risk recipient strategies
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
CYCLOSPORIN;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
OKT 3;
PREDNISONE;
TACROLIMUS;
THYMOCYTE ANTIBODY;
ADOLESCENT;
ADULT;
CHILD;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOUBLE BLIND PROCEDURE;
GRAFT REJECTION;
HIGH RISK PATIENT;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INFANT;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
ORGAN TRANSPLANTATION;
PANCREAS TRANSPLANTATION;
PRIORITY JOURNAL;
AFRICAN AMERICANS;
AFRICAN CONTINENTAL ANCESTRY GROUP;
CHILD;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
ISOANTIBODIES;
KIDNEY TRANSPLANTATION;
PANCREAS TRANSPLANTATION;
REGISTRIES;
RISK FACTORS;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 0033025862
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(98)01520-6 Document Type: Conference Paper |
Times cited : (6)
|
References (26)
|